The
Cardiovascular
Knowledge base
Tools
Drugs
Courses
Tests
Atlas
⌘K
Log in
Become a member
Tools
/
Procedure Codes
/
3E0
Calculators
ICD-10-CM
Procedure Codes
Reference values
Procedures
Quick references
loading…
Procedure Codes
/
ICD-10-PCS
/
Administration
/
Physiological Systems and Anatomical Regions
/
Introduction
3E0
Introduction
Back
3E00X05
Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach
→
3E00X0M
Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
→
3E00X28
Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach
→
3E00X29
Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach
→
3E00X3Z
Introduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach
→
3E00X4Z
Introduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach
→
3E00XBZ
Introduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach
→
3E00XGC
Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach
→
3E00XKZ
Introduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach
→
3E00XMZ
Introduction of Pigment into Skin and Mucous Membranes, External Approach
→
3E00XNZ
Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach
→
3E00XTZ
Introduction of Destructive Agent into Skin and Mucous Membranes, External Approach
→
3E0102A
Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach
→
3E01305
Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach
→
3E0130M
Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
→
3E01328
Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach
→
3E01329
Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach
→
3E0132A
Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach
→
3E0133Z
Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach
→
3E01340
Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach
→
3E0134Z
Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach
→
3E0136Z
Introduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach
→
3E0137Z
Introduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach
→
3E013BZ
Introduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach
→
3E013GC
Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach
→
3E013HZ
Introduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach
→
3E013KZ
Introduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach
→
3E013NZ
Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach
→
3E013TZ
Introduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach
→
3E013VG
Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach
→
3E013VJ
Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach
→
3E02305
Introduction of Other Antineoplastic into Muscle, Percutaneous Approach
→
3E0230M
Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
→
3E02328
Introduction of Oxazolidinones into Muscle, Percutaneous Approach
→
3E02329
Introduction of Other Anti-infective into Muscle, Percutaneous Approach
→
3E0233Z
Introduction of Anti-inflammatory into Muscle, Percutaneous Approach
→
3E02340
Introduction of Influenza Vaccine into Muscle, Percutaneous Approach
→
3E0234Z
Introduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach
→
3E0236Z
Introduction of Nutritional Substance into Muscle, Percutaneous Approach
→
3E0237Z
Introduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach
→
3E023BZ
Introduction of Anesthetic Agent into Muscle, Percutaneous Approach
→
3E023GC
Introduction of Other Therapeutic Substance into Muscle, Percutaneous Approach
→
3E023HZ
Introduction of Radioactive Substance into Muscle, Percutaneous Approach
→
3E023KZ
Introduction of Other Diagnostic Substance into Muscle, Percutaneous Approach
→
3E023NZ
Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach
→
3E023TZ
Introduction of Destructive Agent into Muscle, Percutaneous Approach
→
3E03002
Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
→
3E03003
Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach
→
3E03005
Introduction of Other Antineoplastic into Peripheral Vein, Open Approach
→
3E0300M
Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
→
3E0300P
Introduction of Clofarabine into Peripheral Vein, Open Approach
→
3E03016
Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open
→
3E03017
Introduction of Other Thrombolytic into Peripheral Vein, Open Approach
→
3E03028
Introduction of Oxazolidinones into Peripheral Vein, Open Approach
→
3E03029
Introduction of Other Anti-infective into Peripheral Vein, Open Approach
→
3E0303Z
Introduction of Anti-inflammatory into Peripheral Vein, Open Approach
→
3E0304Z
Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach
→
3E0306Z
Introduction of Nutritional Substance into Peripheral Vein, Open Approach
→
3E0307Z
Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach
→
3E030FZ
Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach
→
3E030GC
Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach
→
3E030GN
Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach
→
3E030HZ
Introduction of Radioactive Substance into Peripheral Vein, Open Approach
→
3E030KZ
Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach
→
3E030NZ
Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach
→
3E030PZ
Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach
→
3E030RZ
Introduction of Antiarrhythmic into Peripheral Vein, Open Approach
→
3E030TZ
Introduction of Destructive Agent into Peripheral Vein, Open Approach
→
3E030U0
Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
→
3E030U1
Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
→
3E030VG
Introduction of Insulin into Peripheral Vein, Open Approach
→
3E030VH
Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach
→
3E030VJ
Introduction of Other Hormone into Peripheral Vein, Open Approach
→
3E030WK
Introduction of Immunostimulator into Peripheral Vein, Open
→
3E030WL
Introduction of Immunosuppressive into Peripheral Vein, Open
→
3E030XZ
Introduction of Vasopressor into Peripheral Vein, Open Approach
→
3E03302
Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
→
3E03303
Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
→
3E03305
Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach
→
3E0330M
Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
→
3E0330P
Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach
→
3E03316
Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous
→
3E03317
Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach
→
3E03328
Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach
→
3E03329
Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach
→
3E0333Z
Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach
→
3E0334Z
Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach
→
3E0336Z
Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach
→
3E0337Z
Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach
→
3E033FZ
Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach
→
3E033GC
Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach
→
3E033GN
Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach
→
3E033GQ
Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach
→
3E033GR
Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach
→
3E033HZ
Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach
→
3E033KZ
Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach
→
3E033NZ
Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach
→
3E033PZ
Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach
→
3E033RZ
Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach
→
3E033TZ
Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach
→
3E033U0
Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
→
3E033U1
Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
→
3E033VG
Introduction of Insulin into Peripheral Vein, Percutaneous Approach
→
3E033VH
Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach
→
3E033VJ
Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach
→
3E033WK
Introduction of Immunostimulator into Peripheral Vein, Percutaneous
→
3E033WL
Introduction of Immunosuppressive into Peripheral Vein, Percutaneous
→
3E033XZ
Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach
→
3E04002
Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
→
3E04003
Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach
→
3E04005
Introduction of Other Antineoplastic into Central Vein, Open Approach
→
3E0400M
Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
→
3E0400P
Introduction of Clofarabine into Central Vein, Open Approach
→
3E04016
Introduction of Recombinant Human-activated Protein C into Central Vein, Open
→
3E04017
Introduction of Other Thrombolytic into Central Vein, Open Approach
→
3E04028
Introduction of Oxazolidinones into Central Vein, Open Approach
→
3E04029
Introduction of Other Anti-infective into Central Vein, Open Approach
→
3E0403Z
Introduction of Anti-inflammatory into Central Vein, Open Approach
→
3E0404Z
Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach
→
3E0406Z
Introduction of Nutritional Substance into Central Vein, Open Approach
→
3E0407Z
Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach
→
3E040FZ
Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach
→
3E040GC
Introduction of Other Therapeutic Substance into Central Vein, Open Approach
→
3E040GN
Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach
→
3E040HZ
Introduction of Radioactive Substance into Central Vein, Open Approach
→
3E040KZ
Introduction of Other Diagnostic Substance into Central Vein, Open Approach
→
3E040NZ
Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach
→
3E040PZ
Introduction of Platelet Inhibitor into Central Vein, Open Approach
→
3E040RZ
Introduction of Antiarrhythmic into Central Vein, Open Approach
→
3E040TZ
Introduction of Destructive Agent into Central Vein, Open Approach
→
3E040VG
Introduction of Insulin into Central Vein, Open Approach
→
3E040VH
Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach
→
3E040VJ
Introduction of Other Hormone into Central Vein, Open Approach
→
3E040WK
Introduction of Immunostimulator into Central Vein, Open
→
3E040WL
Introduction of Immunosuppressive into Central Vein, Open
→
3E040XZ
Introduction of Vasopressor into Central Vein, Open Approach
→
3E04302
Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
→
3E04303
Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach
→
3E04305
Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
→
3E0430M
Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
→
3E0430P
Introduction of Clofarabine into Central Vein, Percutaneous Approach
→
3E04316
Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous
→
3E04317
Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach
→
3E04328
Introduction of Oxazolidinones into Central Vein, Percutaneous Approach
→
3E04329
Introduction of Other Anti-infective into Central Vein, Percutaneous Approach
→
3E0433Z
Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach
→
3E0434Z
Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach
→
3E0436Z
Introduction of Nutritional Substance into Central Vein, Percutaneous Approach
→
3E0437Z
Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach
→
3E043FZ
Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach
→
3E043GC
Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach
→
3E043GN
Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach
→
3E043GQ
Introduction of Glucarpidase into Central Vein, Percutaneous Approach
→
3E043GR
Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach
→
3E043HZ
Introduction of Radioactive Substance into Central Vein, Percutaneous Approach
→
3E043KZ
Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach
→
3E043NZ
Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach
→
3E043PZ
Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach
→
3E043RZ
Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach
→
3E043TZ
Introduction of Destructive Agent into Central Vein, Percutaneous Approach
→
3E043VG
Introduction of Insulin into Central Vein, Percutaneous Approach
→
3E043VH
Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach
→
3E043VJ
Introduction of Other Hormone into Central Vein, Percutaneous Approach
→
3E043WK
Introduction of Immunostimulator into Central Vein, Percutaneous
→
3E043WL
Introduction of Immunosuppressive into Central Vein, Percutaneous
→
3E043XZ
Introduction of Vasopressor into Central Vein, Percutaneous Approach
→
3E05002
Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
→
3E05003
Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach
→
3E05005
Introduction of Other Antineoplastic into Peripheral Artery, Open Approach
→
3E0500M
Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
→
3E0500P
Introduction of Clofarabine into Peripheral Artery, Open Approach
→
3E05016
Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open
→
3E05017
Introduction of Other Thrombolytic into Peripheral Artery, Open Approach
→
3E05028
Introduction of Oxazolidinones into Peripheral Artery, Open Approach
→
3E05029
Introduction of Other Anti-infective into Peripheral Artery, Open Approach
→
3E0503Z
Introduction of Anti-inflammatory into Peripheral Artery, Open Approach
→
3E0504Z
Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach
→
3E0506Z
Introduction of Nutritional Substance into Peripheral Artery, Open Approach
→
3E0507Z
Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach
→
3E050FZ
Introduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach
→
3E050GC
Introduction of Other Therapeutic Substance into Peripheral Artery, Open Approach
→
3E050GN
Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach
→
3E050HZ
Introduction of Radioactive Substance into Peripheral Artery, Open Approach
→
3E050KZ
Introduction of Other Diagnostic Substance into Peripheral Artery, Open Approach
→
3E050NZ
Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach
→
3E050PZ
Introduction of Platelet Inhibitor into Peripheral Artery, Open Approach
→
3E050RZ
Introduction of Antiarrhythmic into Peripheral Artery, Open Approach
→
3E050TZ
Introduction of Destructive Agent into Peripheral Artery, Open Approach
→
3E050VG
Introduction of Insulin into Peripheral Artery, Open Approach
→
3E050VH
Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach
→
3E050VJ
Introduction of Other Hormone into Peripheral Artery, Open Approach
→
3E050WK
Introduction of Immunostimulator into Peripheral Artery, Open
→
3E050WL
Introduction of Immunosuppressive into Peripheral Artery, Open
→
3E050XZ
Introduction of Vasopressor into Peripheral Artery, Open Approach
→
3E05302
Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
→
3E05303
Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
→
3E05305
Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach
→
3E0530M
Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
→
3E0530P
Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach
→
3E05316
Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous
→
3E05317
Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach
→
3E05328
Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach
→
3E05329
Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach
→
3E0533Z
Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach
→
3E0534Z
Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach
→
3E0536Z
Introduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach
→
3E0537Z
Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach
→
3E053FZ
Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach
→
3E053GC
Introduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach
→
3E053GN
Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach
→
3E053HZ
Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach
→
3E053KZ
Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach
→
3E053NZ
Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach
→
3E053PZ
Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach
→
3E053RZ
Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach
→
3E053TZ
Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach
→
3E053VG
Introduction of Insulin into Peripheral Artery, Percutaneous Approach
→
3E053VH
Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach
→
3E053VJ
Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach
→
3E053WK
Introduction of Immunostimulator into Peripheral Artery, Percutaneous
→
3E053WL
Introduction of Immunosuppressive into Peripheral Artery, Percutaneous
→
3E053XZ
Introduction of Vasopressor into Peripheral Artery, Percutaneous Approach
→
3E06002
Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
→
3E06003
Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach
→
3E06005
Introduction of Other Antineoplastic into Central Artery, Open Approach
→
3E0600M
Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
→
3E0600P
Introduction of Clofarabine into Central Artery, Open Approach
→
3E06016
Introduction of Recombinant Human-activated Protein C into Central Artery, Open
→
3E06017
Introduction of Other Thrombolytic into Central Artery, Open Approach
→
3E06028
Introduction of Oxazolidinones into Central Artery, Open Approach
→
3E06029
Introduction of Other Anti-infective into Central Artery, Open Approach
→
3E0603Z
Introduction of Anti-inflammatory into Central Artery, Open Approach
→
3E0604Z
Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach
→
3E0606Z
Introduction of Nutritional Substance into Central Artery, Open Approach
→
3E0607Z
Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach
→
3E060FZ
Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach
→
3E060GC
Introduction of Other Therapeutic Substance into Central Artery, Open Approach
→
3E060GN
Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach
→
3E060HZ
Introduction of Radioactive Substance into Central Artery, Open Approach
→
3E060KZ
Introduction of Other Diagnostic Substance into Central Artery, Open Approach
→
3E060NZ
Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach
→
3E060PZ
Introduction of Platelet Inhibitor into Central Artery, Open Approach
→
3E060RZ
Introduction of Antiarrhythmic into Central Artery, Open Approach
→
3E060TZ
Introduction of Destructive Agent into Central Artery, Open Approach
→
3E060VG
Introduction of Insulin into Central Artery, Open Approach
→
3E060VH
Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach
→
3E060VJ
Introduction of Other Hormone into Central Artery, Open Approach
→
3E060WK
Introduction of Immunostimulator into Central Artery, Open
→
3E060WL
Introduction of Immunosuppressive into Central Artery, Open
→
3E060XZ
Introduction of Vasopressor into Central Artery, Open Approach
→
3E06302
Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
→
3E06303
Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach
→
3E06305
Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach
→
3E0630M
Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
→
3E0630P
Introduction of Clofarabine into Central Artery, Percutaneous Approach
→
3E06316
Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous
→
3E06317
Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach
→
3E06328
Introduction of Oxazolidinones into Central Artery, Percutaneous Approach
→
3E06329
Introduction of Other Anti-infective into Central Artery, Percutaneous Approach
→
3E0633Z
Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach
→
3E0634Z
Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach
→
3E0636Z
Introduction of Nutritional Substance into Central Artery, Percutaneous Approach
→
3E0637Z
Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach
→
3E063FZ
Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach
→
3E063GC
Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach
→
3E063GN
Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach
→
3E063HZ
Introduction of Radioactive Substance into Central Artery, Percutaneous Approach
→
3E063KZ
Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach
→
3E063NZ
Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach
→
3E063PZ
Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach
→
3E063RZ
Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach
→
3E063TZ
Introduction of Destructive Agent into Central Artery, Percutaneous Approach
→
3E063VG
Introduction of Insulin into Central Artery, Percutaneous Approach
→
3E063VH
Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach
→
3E063VJ
Introduction of Other Hormone into Central Artery, Percutaneous Approach
→
3E063WK
Introduction of Immunostimulator into Central Artery, Percutaneous
→
3E063WL
Introduction of Immunosuppressive into Central Artery, Percutaneous
→
3E063XZ
Introduction of Vasopressor into Central Artery, Percutaneous Approach
→
3E07016
Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open
→
3E07017
Introduction of Other Thrombolytic into Coronary Artery, Open Approach
→
3E070GC
Introduction of Other Therapeutic Substance into Coronary Artery, Open Approach
→
3E070KZ
Introduction of Other Diagnostic Substance into Coronary Artery, Open Approach
→
3E070PZ
Introduction of Platelet Inhibitor into Coronary Artery, Open Approach
→
3E07316
Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous
→
3E07317
Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach
→
3E073GC
Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach
→
3E073KZ
Introduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach
→
3E073PZ
Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach
→
3E074GC
Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach
→
3E08016
Introduction of Recombinant Human-activated Protein C into Heart, Open
→
3E08017
Introduction of Other Thrombolytic into Heart, Open Approach
→
3E080GC
Introduction of Other Therapeutic Substance into Heart, Open Approach
→
3E080KZ
Introduction of Other Diagnostic Substance into Heart, Open Approach
→
3E080PZ
Introduction of Platelet Inhibitor into Heart, Open Approach
→
3E08316
Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous
→
3E08317
Introduction of Other Thrombolytic into Heart, Percutaneous Approach
→
3E083GC
Introduction of Other Therapeutic Substance into Heart, Percutaneous Approach
→
3E083KZ
Introduction of Other Diagnostic Substance into Heart, Percutaneous Approach
→
3E083PZ
Introduction of Platelet Inhibitor into Heart, Percutaneous Approach
→
3E084GC
Introduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach
→
3E09305
Introduction of Other Antineoplastic into Nose, Percutaneous Approach
→
3E0930M
Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
→
3E09328
Introduction of Oxazolidinones into Nose, Percutaneous Approach
→
3E09329
Introduction of Other Anti-infective into Nose, Percutaneous Approach
→
3E0933Z
Introduction of Anti-inflammatory into Nose, Percutaneous Approach
→
3E0934Z
Introduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach
→
3E093BZ
Introduction of Anesthetic Agent into Nose, Percutaneous Approach
→
3E093GC
Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach
→
3E093HZ
Introduction of Radioactive Substance into Nose, Percutaneous Approach
→
3E093KZ
Introduction of Other Diagnostic Substance into Nose, Percutaneous Approach
→
3E093NZ
Introduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach
→
3E093TZ
Introduction of Destructive Agent into Nose, Percutaneous Approach
→
3E09705
Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening
→
3E0970M
Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
→
3E09728
Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening
→
3E09729
Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening
→
3E0973Z
Introduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening
→
3E0974Z
Introduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening
→
3E097BZ
Introduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening
→
3E097GC
Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening
→
3E097HZ
Introduction of Radioactive Substance into Nose, Via Natural or Artificial Opening
→
3E097KZ
Introduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening
→
3E097NZ
Introduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening
→
3E097TZ
Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening
→
3E09X05
Introduction of Other Antineoplastic into Nose, External Approach
→
3E09X0M
Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
→
3E09X28
Introduction of Oxazolidinones into Nose, External Approach
→
3E09X29
Introduction of Other Anti-infective into Nose, External Approach
→
3E09X3Z
Introduction of Anti-inflammatory into Nose, External Approach
→
3E09X4Z
Introduction of Serum, Toxoid and Vaccine into Nose, External Approach
→
3E09XBZ
Introduction of Anesthetic Agent into Nose, External Approach
→
3E09XGC
Introduction of Other Therapeutic Substance into Nose, External Approach
→
3E09XHZ
Introduction of Radioactive Substance into Nose, External Approach
→
3E09XKZ
Introduction of Other Diagnostic Substance into Nose, External Approach
→
3E09XNZ
Introduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach
→
3E09XTZ
Introduction of Destructive Agent into Nose, External Approach
→
3E0A305
Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach
→
3E0A30M
Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
→
3E0A3GC
Introduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach
→
3E0B304
Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach
→
3E0B305
Introduction of Other Antineoplastic into Ear, Percutaneous Approach
→
3E0B30M
Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
→
3E0B328
Introduction of Oxazolidinones into Ear, Percutaneous Approach
→
3E0B329
Introduction of Other Anti-infective into Ear, Percutaneous Approach
→
3E0B33Z
Introduction of Anti-inflammatory into Ear, Percutaneous Approach
→
3E0B3BZ
Introduction of Anesthetic Agent into Ear, Percutaneous Approach
→
3E0B3GC
Introduction of Other Therapeutic Substance into Ear, Percutaneous Approach
→
3E0B3HZ
Introduction of Radioactive Substance into Ear, Percutaneous Approach
→
3E0B3KZ
Introduction of Other Diagnostic Substance into Ear, Percutaneous Approach
→
3E0B3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach
→
3E0B3TZ
Introduction of Destructive Agent into Ear, Percutaneous Approach
→
3E0B704
Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening
→
3E0B705
Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening
→
3E0B70M
Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
→
3E0B728
Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening
→
3E0B729
Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening
→
3E0B73Z
Introduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening
→
3E0B7BZ
Introduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening
→
3E0B7GC
Introduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening
→
3E0B7HZ
Introduction of Radioactive Substance into Ear, Via Natural or Artificial Opening
→
3E0B7KZ
Introduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening
→
3E0B7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening
→
3E0B7TZ
Introduction of Destructive Agent into Ear, Via Natural or Artificial Opening
→
3E0BX04
Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach
→
3E0BX05
Introduction of Other Antineoplastic into Ear, External Approach
→
3E0BX0M
Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
→
3E0BX28
Introduction of Oxazolidinones into Ear, External Approach
→
3E0BX29
Introduction of Other Anti-infective into Ear, External Approach
→
3E0BX3Z
Introduction of Anti-inflammatory into Ear, External Approach
→
3E0BXBZ
Introduction of Anesthetic Agent into Ear, External Approach
→
3E0BXGC
Introduction of Other Therapeutic Substance into Ear, External Approach
→
3E0BXHZ
Introduction of Radioactive Substance into Ear, External Approach
→
3E0BXKZ
Introduction of Other Diagnostic Substance into Ear, External Approach
→
3E0BXNZ
Introduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach
→
3E0BXTZ
Introduction of Destructive Agent into Ear, External Approach
→
3E0C304
Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach
→
3E0C305
Introduction of Other Antineoplastic into Eye, Percutaneous Approach
→
3E0C30M
Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
→
3E0C328
Introduction of Oxazolidinones into Eye, Percutaneous Approach
→
3E0C329
Introduction of Other Anti-infective into Eye, Percutaneous Approach
→
3E0C33Z
Introduction of Anti-inflammatory into Eye, Percutaneous Approach
→
3E0C3BZ
Introduction of Anesthetic Agent into Eye, Percutaneous Approach
→
3E0C3GC
Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach
→
3E0C3HZ
Introduction of Radioactive Substance into Eye, Percutaneous Approach
→
3E0C3KZ
Introduction of Other Diagnostic Substance into Eye, Percutaneous Approach
→
3E0C3MZ
Introduction of Pigment into Eye, Percutaneous Approach
→
3E0C3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach
→
3E0C3SF
Introduction of Other Gas into Eye, Percutaneous Approach
→
3E0C3TZ
Introduction of Destructive Agent into Eye, Percutaneous Approach
→
3E0C704
Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening
→
3E0C705
Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening
→
3E0C70M
Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
→
3E0C728
Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening
→
3E0C729
Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening
→
3E0C73Z
Introduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening
→
3E0C7BZ
Introduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening
→
3E0C7GC
Introduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening
→
3E0C7HZ
Introduction of Radioactive Substance into Eye, Via Natural or Artificial Opening
→
3E0C7KZ
Introduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening
→
3E0C7MZ
Introduction of Pigment into Eye, Via Natural or Artificial Opening
→
3E0C7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening
→
3E0C7SF
Introduction of Other Gas into Eye, Via Natural or Artificial Opening
→
3E0C7TZ
Introduction of Destructive Agent into Eye, Via Natural or Artificial Opening
→
3E0CX04
Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach
→
3E0CX05
Introduction of Other Antineoplastic into Eye, External Approach
→
3E0CX0M
Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
→
3E0CX28
Introduction of Oxazolidinones into Eye, External Approach
→
3E0CX29
Introduction of Other Anti-infective into Eye, External Approach
→
3E0CX3Z
Introduction of Anti-inflammatory into Eye, External Approach
→
3E0CXBZ
Introduction of Anesthetic Agent into Eye, External Approach
→
3E0CXGC
Introduction of Other Therapeutic Substance into Eye, External Approach
→
3E0CXHZ
Introduction of Radioactive Substance into Eye, External Approach
→
3E0CXKZ
Introduction of Other Diagnostic Substance into Eye, External Approach
→
3E0CXMZ
Introduction of Pigment into Eye, External Approach
→
3E0CXNZ
Introduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach
→
3E0CXSF
Introduction of Other Gas into Eye, External Approach
→
3E0CXTZ
Introduction of Destructive Agent into Eye, External Approach
→
3E0D304
Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach
→
3E0D305
Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach
→
3E0D30M
Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
→
3E0D328
Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach
→
3E0D329
Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach
→
3E0D33Z
Introduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach
→
3E0D34Z
Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach
→
3E0D36Z
Introduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach
→
3E0D37Z
Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach
→
3E0D3BZ
Introduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach
→
3E0D3GC
Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach
→
3E0D3HZ
Introduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach
→
3E0D3KZ
Introduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach
→
3E0D3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach
→
3E0D3RZ
Introduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach
→
3E0D3TZ
Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach
→
3E0D704
Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D705
Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D70M
Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D728
Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D729
Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D73Z
Introduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D74Z
Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D76Z
Introduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D77Z
Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7BZ
Introduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7GC
Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7HZ
Introduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7KZ
Introduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7RZ
Introduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0D7TZ
Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening
→
3E0DX04
Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach
→
3E0DX05
Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach
→
3E0DX0M
Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
→
3E0DX28
Introduction of Oxazolidinones into Mouth and Pharynx, External Approach
→
3E0DX29
Introduction of Other Anti-infective into Mouth and Pharynx, External Approach
→
3E0DX3Z
Introduction of Anti-inflammatory into Mouth and Pharynx, External Approach
→
3E0DX4Z
Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach
→
3E0DX6Z
Introduction of Nutritional Substance into Mouth and Pharynx, External Approach
→
3E0DX7Z
Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach
→
3E0DXBZ
Introduction of Anesthetic Agent into Mouth and Pharynx, External Approach
→
3E0DXGC
Introduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach
→
3E0DXHZ
Introduction of Radioactive Substance into Mouth and Pharynx, External Approach
→
3E0DXKZ
Introduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach
→
3E0DXNZ
Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach
→
3E0DXRZ
Introduction of Antiarrhythmic into Mouth and Pharynx, External Approach
→
3E0DXTZ
Introduction of Destructive Agent into Mouth and Pharynx, External Approach
→
3E0E304
Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach
→
3E0E305
Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach
→
3E0E30M
Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
→
3E0E328
Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach
→
3E0E329
Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach
→
3E0E33Z
Introduction of Anti-inflammatory into Products of Conception, Percutaneous Approach
→
3E0E36Z
Introduction of Nutritional Substance into Products of Conception, Percutaneous Approach
→
3E0E37Z
Introduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach
→
3E0E3BZ
Introduction of Anesthetic Agent into Products of Conception, Percutaneous Approach
→
3E0E3GC
Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach
→
3E0E3HZ
Introduction of Radioactive Substance into Products of Conception, Percutaneous Approach
→
3E0E3KZ
Introduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach
→
3E0E3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach
→
3E0E3SF
Introduction of Other Gas into Products of Conception, Percutaneous Approach
→
3E0E3TZ
Introduction of Destructive Agent into Products of Conception, Percutaneous Approach
→
3E0E4GC
Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach
→
3E0E704
Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening
→
3E0E705
Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening
→
3E0E70M
Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
→
3E0E728
Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening
→
3E0E729
Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening
→
3E0E73Z
Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening
→
3E0E76Z
Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening
→
3E0E77Z
Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening
→
3E0E7BZ
Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening
→
3E0E7GC
Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening
→
3E0E7HZ
Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening
→
3E0E7KZ
Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening
→
3E0E7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening
→
3E0E7SF
Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening
→
3E0E7TZ
Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening
→
3E0E804
Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E805
Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E80M
Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E828
Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E829
Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E83Z
Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E86Z
Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E87Z
Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8BZ
Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8GC
Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8HZ
Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8KZ
Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8SF
Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0E8TZ
Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic
→
3E0F304
Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Percutaneous Approach
→
3E0F305
Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach
→
3E0F30M
Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach
→
3E0F328
Introduction of Oxazolidinones into Respiratory Tract, Percutaneous Approach
→
3E0F329
Introduction of Other Anti-infective into Respiratory Tract, Percutaneous Approach
→
3E0F33Z
Introduction of Anti-inflammatory into Respiratory Tract, Percutaneous Approach
→
3E0F36Z
Introduction of Nutritional Substance into Respiratory Tract, Percutaneous Approach
→
3E0F37Z
Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Percutaneous Approach
→
3E0F3BZ
Introduction of Anesthetic Agent into Respiratory Tract, Percutaneous Approach
→
3E0F3GC
Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Approach
→
3E0F3HZ
Introduction of Radioactive Substance into Respiratory Tract, Percutaneous Approach
→
3E0F3KZ
Introduction of Other Diagnostic Substance into Respiratory Tract, Percutaneous Approach
→
3E0F3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Percutaneous Approach
→
3E0F3SD
Introduction of Nitric Oxide Gas into Respiratory Tract, Percutaneous Approach
→
3E0F3SF
Introduction of Other Gas into Respiratory Tract, Percutaneous Approach
→
3E0F3TZ
Introduction of Destructive Agent into Respiratory Tract, Percutaneous Approach
→
3E0F4GC
Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Endoscopic Approach
→
3E0F704
Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F705
Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F70M
Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F728
Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F729
Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F73Z
Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F76Z
Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F77Z
Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7BZ
Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7GC
Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7HZ
Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7KZ
Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7SD
Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7SF
Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F7TZ
Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening
→
3E0F804
Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F805
Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F80M
Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F828
Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F829
Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F83Z
Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F86Z
Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F87Z
Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8BZ
Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8GC
Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8HZ
Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8KZ
Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8SD
Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8SF
Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0F8TZ
Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→
3E0G304
Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Percutaneous Approach
→
3E0G305
Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach
→
3E0G30M
Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach
→
3E0G328
Introduction of Oxazolidinones into Upper GI, Percutaneous Approach
→
3E0G329
Introduction of Other Anti-infective into Upper GI, Percutaneous Approach
→
3E0G33Z
Introduction of Anti-inflammatory into Upper GI, Percutaneous Approach
→
3E0G36Z
Introduction of Nutritional Substance into Upper GI, Percutaneous Approach
→
3E0G37Z
Introduction of Electrolytic and Water Balance Substance into Upper GI, Percutaneous Approach
→
3E0G3BZ
Introduction of Anesthetic Agent into Upper GI, Percutaneous Approach
→
3E0G3GC
Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Approach
→
3E0G3HZ
Introduction of Radioactive Substance into Upper GI, Percutaneous Approach
→
3E0G3KZ
Introduction of Other Diagnostic Substance into Upper GI, Percutaneous Approach
→
3E0G3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Percutaneous Approach
→
3E0G3SF
Introduction of Other Gas into Upper GI, Percutaneous Approach
→
3E0G3TZ
Introduction of Destructive Agent into Upper GI, Percutaneous Approach
→
3E0G4GC
Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Endoscopic Approach
→
3E0G704
Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening
→
3E0G705
Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening
→
3E0G70M
Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening
→
3E0G728
Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening
→
3E0G729
Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening
→
3E0G73Z
Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening
→
3E0G76Z
Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening
→
3E0G77Z
Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening
→
3E0G7BZ
Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening
→
3E0G7GC
Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening
→
3E0G7HZ
Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening
→
3E0G7KZ
Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening
→
3E0G7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening
→
3E0G7SF
Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening
→
3E0G7TZ
Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening
→
3E0G804
Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G805
Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G80M
Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G828
Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G829
Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G83Z
Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G86Z
Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G87Z
Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8BZ
Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8GC
Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8HZ
Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8KZ
Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8SF
Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0G8TZ
Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic
→
3E0H304
Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Percutaneous Approach
→
3E0H305
Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach
→
3E0H30M
Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach
→
3E0H328
Introduction of Oxazolidinones into Lower GI, Percutaneous Approach
→
3E0H329
Introduction of Other Anti-infective into Lower GI, Percutaneous Approach
→
3E0H33Z
Introduction of Anti-inflammatory into Lower GI, Percutaneous Approach
→
3E0H36Z
Introduction of Nutritional Substance into Lower GI, Percutaneous Approach
→
3E0H37Z
Introduction of Electrolytic and Water Balance Substance into Lower GI, Percutaneous Approach
→
3E0H3BZ
Introduction of Anesthetic Agent into Lower GI, Percutaneous Approach
→
3E0H3GC
Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach
→
3E0H3HZ
Introduction of Radioactive Substance into Lower GI, Percutaneous Approach
→
3E0H3KZ
Introduction of Other Diagnostic Substance into Lower GI, Percutaneous Approach
→
3E0H3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Percutaneous Approach
→
3E0H3SF
Introduction of Other Gas into Lower GI, Percutaneous Approach
→
3E0H3TZ
Introduction of Destructive Agent into Lower GI, Percutaneous Approach
→
3E0H4GC
Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Endoscopic Approach
→
3E0H704
Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening
→
3E0H705
Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening
→
3E0H70M
Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening
→
3E0H728
Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening
→
3E0H729
Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening
→
3E0H73Z
Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening
→
3E0H76Z
Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening
→
3E0H77Z
Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening
→
3E0H7BZ
Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening
→
3E0H7GC
Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening
→
3E0H7HZ
Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening
→
3E0H7KZ
Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening
→
3E0H7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening
→
3E0H7SF
Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening
→
3E0H7TZ
Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening
→
3E0H804
Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H805
Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H80M
Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H828
Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H829
Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H83Z
Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H86Z
Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H87Z
Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8BZ
Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8GC
Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8HZ
Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8KZ
Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8SF
Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0H8TZ
Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic
→
3E0J304
Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J305
Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J30M
Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J328
Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J329
Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J33Z
Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J36Z
Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J37Z
Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3BZ
Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3GC
Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3HZ
Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3KZ
Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3SF
Introduction of Other Gas into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3TZ
Introduction of Destructive Agent into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3U0
Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J3U1
Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach
→
3E0J4GC
Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Endoscopic Approach
→
3E0J704
Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J705
Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J70M
Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J728
Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J729
Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J73Z
Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J76Z
Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J77Z
Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7BZ
Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7GC
Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7HZ
Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7KZ
Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7SF
Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7TZ
Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7U0
Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J7U1
Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→
3E0J804
Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J805
Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J80M
Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J828
Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J829
Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J83Z
Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J86Z
Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J87Z
Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8BZ
Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8GC
Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8HZ
Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8KZ
Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8SF
Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8TZ
Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8U0
Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0J8U1
Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K304
Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Percutaneous Approach
→
3E0K305
Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach
→
3E0K30M
Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach
→
3E0K328
Introduction of Oxazolidinones into Genitourinary Tract, Percutaneous Approach
→
3E0K329
Introduction of Other Anti-infective into Genitourinary Tract, Percutaneous Approach
→
3E0K33Z
Introduction of Anti-inflammatory into Genitourinary Tract, Percutaneous Approach
→
3E0K36Z
Introduction of Nutritional Substance into Genitourinary Tract, Percutaneous Approach
→
3E0K37Z
Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Percutaneous Approach
→
3E0K3BZ
Introduction of Anesthetic Agent into Genitourinary Tract, Percutaneous Approach
→
3E0K3GC
Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Approach
→
3E0K3HZ
Introduction of Radioactive Substance into Genitourinary Tract, Percutaneous Approach
→
3E0K3KZ
Introduction of Other Diagnostic Substance into Genitourinary Tract, Percutaneous Approach
→
3E0K3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Percutaneous Approach
→
3E0K3SF
Introduction of Other Gas into Genitourinary Tract, Percutaneous Approach
→
3E0K3TZ
Introduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach
→
3E0K4GC
Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Endoscopic Approach
→
3E0K704
Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K705
Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K70M
Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K728
Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K729
Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K73Z
Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K76Z
Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K77Z
Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7BZ
Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7GC
Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7HZ
Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7KZ
Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7SF
Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K7TZ
Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening
→
3E0K804
Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K805
Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K80M
Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K828
Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K829
Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K83Z
Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K86Z
Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K87Z
Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8BZ
Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8GC
Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8HZ
Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8KZ
Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8SF
Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0K8TZ
Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→
3E0L05Z
Introduction of Adhesion Barrier into Pleural Cavity, Open Approach
→
3E0L304
Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Percutaneous Approach
→
3E0L305
Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach
→
3E0L30M
Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach
→
3E0L317
Introduction of Other Thrombolytic into Pleural Cavity, Percutaneous Approach
→
3E0L328
Introduction of Oxazolidinones into Pleural Cavity, Percutaneous Approach
→
3E0L329
Introduction of Other Anti-infective into Pleural Cavity, Percutaneous Approach
→
3E0L33Z
Introduction of Anti-inflammatory into Pleural Cavity, Percutaneous Approach
→
3E0L35Z
Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Approach
→
3E0L36Z
Introduction of Nutritional Substance into Pleural Cavity, Percutaneous Approach
→
3E0L37Z
Introduction of Electrolytic and Water Balance Substance into Pleural Cavity, Percutaneous Approach
→
3E0L3BZ
Introduction of Anesthetic Agent into Pleural Cavity, Percutaneous Approach
→
3E0L3GC
Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Approach
→
3E0L3HZ
Introduction of Radioactive Substance into Pleural Cavity, Percutaneous Approach
→
3E0L3KZ
Introduction of Other Diagnostic Substance into Pleural Cavity, Percutaneous Approach
→
3E0L3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Pleural Cavity, Percutaneous Approach
→
3E0L3SF
Introduction of Other Gas into Pleural Cavity, Percutaneous Approach
→
3E0L3TZ
Introduction of Destructive Agent into Pleural Cavity, Percutaneous Approach
→
3E0L45Z
Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Endoscopic Approach
→
3E0L4GC
Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Endoscopic Approach
→
3E0L704
Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Via Natural or Artificial Opening
→
3E0L705
Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening
→
3E0L70M
Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening
→
3E0L7SF
Introduction of Other Gas into Pleural Cavity, Via Natural or Artificial Opening
→
3E0M05Z
Introduction of Adhesion Barrier into Peritoneal Cavity, Open Approach
→
3E0M304
Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Percutaneous Approach
→
3E0M305
Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach
→
3E0M30M
Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach
→
3E0M30Y
Introduction of Hyperthermic Antineoplastic into Peritoneal Cavity, Percutaneous Approach
→
3E0M328
Introduction of Oxazolidinones into Peritoneal Cavity, Percutaneous Approach
→
3E0M329
Introduction of Other Anti-infective into Peritoneal Cavity, Percutaneous Approach
→
3E0M33Z
Introduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach
→
3E0M35Z
Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Approach
→
3E0M36Z
Introduction of Nutritional Substance into Peritoneal Cavity, Percutaneous Approach
→
3E0M37Z
Introduction of Electrolytic and Water Balance Substance into Peritoneal Cavity, Percutaneous Approach
→
3E0M3BZ
Introduction of Anesthetic Agent into Peritoneal Cavity, Percutaneous Approach
→
3E0M3GC
Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Approach
→
3E0M3HZ
Introduction of Radioactive Substance into Peritoneal Cavity, Percutaneous Approach
→
3E0M3KZ
Introduction of Other Diagnostic Substance into Peritoneal Cavity, Percutaneous Approach
→
3E0M3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Peritoneal Cavity, Percutaneous Approach
→
3E0M3SF
Introduction of Other Gas into Peritoneal Cavity, Percutaneous Approach
→
3E0M3TZ
Introduction of Destructive Agent into Peritoneal Cavity, Percutaneous Approach
→
3E0M45Z
Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Endoscopic Approach
→
3E0M4GC
Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Endoscopic Approach
→
3E0M704
Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Via Natural or Artificial Opening
→
3E0M705
Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening
→
3E0M70M
Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening
→
3E0M7SF
Introduction of Other Gas into Peritoneal Cavity, Via Natural or Artificial Opening
→
3E0N304
Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Percutaneous Approach
→
3E0N305
Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach
→
3E0N30M
Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach
→
3E0N328
Introduction of Oxazolidinones into Male Reproductive, Percutaneous Approach
→
3E0N329
Introduction of Other Anti-infective into Male Reproductive, Percutaneous Approach
→
3E0N33Z
Introduction of Anti-inflammatory into Male Reproductive, Percutaneous Approach
→
3E0N36Z
Introduction of Nutritional Substance into Male Reproductive, Percutaneous Approach
→
3E0N37Z
Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Percutaneous Approach
→
3E0N3BZ
Introduction of Anesthetic Agent into Male Reproductive, Percutaneous Approach
→
3E0N3GC
Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Approach
→
3E0N3HZ
Introduction of Radioactive Substance into Male Reproductive, Percutaneous Approach
→
3E0N3KZ
Introduction of Other Diagnostic Substance into Male Reproductive, Percutaneous Approach
→
3E0N3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Percutaneous Approach
→
3E0N3SF
Introduction of Other Gas into Male Reproductive, Percutaneous Approach
→
3E0N3TZ
Introduction of Destructive Agent into Male Reproductive, Percutaneous Approach
→
3E0N4GC
Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Endoscopic Approach
→
3E0N704
Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening
→
3E0N705
Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening
→
3E0N70M
Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening
→
3E0N728
Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening
→
3E0N729
Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening
→
3E0N73Z
Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening
→
3E0N76Z
Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening
→
3E0N77Z
Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7BZ
Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7GC
Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7HZ
Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7KZ
Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7SF
Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening
→
3E0N7TZ
Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening
→
3E0N804
Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N805
Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N80M
Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N828
Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N829
Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N83Z
Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N86Z
Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N87Z
Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8BZ
Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8GC
Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8HZ
Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8KZ
Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8SF
Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0N8TZ
Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P05Z
Introduction of Adhesion Barrier into Female Reproductive, Open Approach
→
3E0P304
Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Percutaneous Approach
→
3E0P305
Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach
→
3E0P30M
Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach
→
3E0P328
Introduction of Oxazolidinones into Female Reproductive, Percutaneous Approach
→
3E0P329
Introduction of Other Anti-infective into Female Reproductive, Percutaneous Approach
→
3E0P33Z
Introduction of Anti-inflammatory into Female Reproductive, Percutaneous Approach
→
3E0P35Z
Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Approach
→
3E0P36Z
Introduction of Nutritional Substance into Female Reproductive, Percutaneous Approach
→
3E0P37Z
Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Percutaneous Approach
→
3E0P3BZ
Introduction of Anesthetic Agent into Female Reproductive, Percutaneous Approach
→
3E0P3GC
Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach
→
3E0P3HZ
Introduction of Radioactive Substance into Female Reproductive, Percutaneous Approach
→
3E0P3KZ
Introduction of Other Diagnostic Substance into Female Reproductive, Percutaneous Approach
→
3E0P3LZ
Introduction of Sperm into Female Reproductive, Percutaneous Approach
→
3E0P3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Percutaneous Approach
→
3E0P3Q0
Introduction of Autologous Fertilized Ovum into Female Reproductive, Percutaneous Approach
→
3E0P3Q1
Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Percutaneous Approach
→
3E0P3SF
Introduction of Other Gas into Female Reproductive, Percutaneous Approach
→
3E0P3TZ
Introduction of Destructive Agent into Female Reproductive, Percutaneous Approach
→
3E0P3VZ
Introduction of Hormone into Female Reproductive, Percutaneous Approach
→
3E0P45Z
Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Endoscopic Approach
→
3E0P4GC
Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Endoscopic Approach
→
3E0P704
Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening
→
3E0P705
Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening
→
3E0P70M
Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening
→
3E0P728
Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening
→
3E0P729
Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening
→
3E0P73Z
Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening
→
3E0P76Z
Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening
→
3E0P77Z
Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7BZ
Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7GC
Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7HZ
Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7KZ
Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7LZ
Introduction of Sperm into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7NZ
Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7Q0
Introduction of Autologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7Q1
Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7SF
Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7TZ
Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening
→
3E0P7VZ
Introduction of Hormone into Female Reproductive, Via Natural or Artificial Opening
→
3E0P804
Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P805
Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P80M
Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P828
Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P829
Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P83Z
Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P86Z
Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P87Z
Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8BZ
Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8GC
Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8HZ
Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8KZ
Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8NZ
Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8SF
Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0P8TZ
Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→
3E0Q004
Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Open Approach
→
3E0Q005
Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach
→
3E0Q00M
Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach
→
3E0Q028
Introduction of Oxazolidinones into Cranial Cavity and Brain, Open Approach
→
3E0Q029
Introduction of Other Anti-infective into Cranial Cavity and Brain, Open Approach
→
3E0Q03Z
Introduction of Anti-inflammatory into Cranial Cavity and Brain, Open Approach
→
3E0Q06Z
Introduction of Nutritional Substance into Cranial Cavity and Brain, Open Approach
→
3E0Q07Z
Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Open Approach
→
3E0Q0AZ
Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Open Approach
→
3E0Q0BZ
Introduction of Anesthetic Agent into Cranial Cavity and Brain, Open Approach
→
3E0Q0E0
Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach
→
3E0Q0E1
Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach
→
3E0Q0GC
Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Open Approach
→
3E0Q0HZ
Introduction of Radioactive Substance into Cranial Cavity and Brain, Open Approach
→
3E0Q0KZ
Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Open Approach
→
3E0Q0NZ
Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Open Approach
→
3E0Q0SF
Introduction of Other Gas into Cranial Cavity and Brain, Open Approach
→
3E0Q0TZ
Introduction of Destructive Agent into Cranial Cavity and Brain, Open Approach
→
3E0Q304
Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q305
Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q30M
Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q328
Introduction of Oxazolidinones into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q329
Introduction of Other Anti-infective into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q33Z
Introduction of Anti-inflammatory into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q36Z
Introduction of Nutritional Substance into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q37Z
Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3AZ
Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3BZ
Introduction of Anesthetic Agent into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3E0
Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3E1
Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3GC
Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3HZ
Introduction of Radioactive Substance into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3KZ
Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3SF
Introduction of Other Gas into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q3TZ
Introduction of Destructive Agent into Cranial Cavity and Brain, Percutaneous Approach
→
3E0Q704
Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Via Natural or Artificial Opening
→
3E0Q705
Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening
→
3E0Q70M
Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening
→
3E0Q7SF
Introduction of Other Gas into Cranial Cavity and Brain, Via Natural or Artificial Opening
→
3E0R0AZ
Introduction of Embryonic Stem Cells into Spinal Canal, Open Approach
→
3E0R0E0
Introduction of Autologous Somatic Stem Cells into Spinal Canal, Open Approach
→
3E0R0E1
Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Open Approach
→
3E0R302
Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
→
3E0R303
Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
→
3E0R304
Introduction of Liquid Brachytherapy Radioisotope into Spinal Canal, Percutaneous Approach
→
3E0R305
Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach
→
3E0R30M
Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach
→
3E0R328
Introduction of Oxazolidinones into Spinal Canal, Percutaneous Approach
→
3E0R329
Introduction of Other Anti-infective into Spinal Canal, Percutaneous Approach
→
3E0R33Z
Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach
→
3E0R36Z
Introduction of Nutritional Substance into Spinal Canal, Percutaneous Approach
→
3E0R37Z
Introduction of Electrolytic and Water Balance Substance into Spinal Canal, Percutaneous Approach
→
3E0R3AZ
Introduction of Embryonic Stem Cells into Spinal Canal, Percutaneous Approach
→
3E0R3BZ
Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach
→
3E0R3E0
Introduction of Autologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach
→
3E0R3E1
Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach
→
3E0R3GC
Introduction of Other Therapeutic Substance into Spinal Canal, Percutaneous Approach
→
3E0R3HZ
Introduction of Radioactive Substance into Spinal Canal, Percutaneous Approach
→
3E0R3KZ
Introduction of Other Diagnostic Substance into Spinal Canal, Percutaneous Approach
→
3E0R3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Spinal Canal, Percutaneous Approach
→
3E0R3SF
Introduction of Other Gas into Spinal Canal, Percutaneous Approach
→
3E0R3TZ
Introduction of Destructive Agent into Spinal Canal, Percutaneous Approach
→
3E0R7SF
Introduction of Other Gas into Spinal Canal, Via Natural or Artificial Opening
→
3E0S302
Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach
→
3E0S303
Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach
→
3E0S304
Introduction of Liquid Brachytherapy Radioisotope into Epidural Space, Percutaneous Approach
→
3E0S305
Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach
→
3E0S30M
Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach
→
3E0S328
Introduction of Oxazolidinones into Epidural Space, Percutaneous Approach
→
3E0S329
Introduction of Other Anti-infective into Epidural Space, Percutaneous Approach
→
3E0S33Z
Introduction of Anti-inflammatory into Epidural Space, Percutaneous Approach
→
3E0S36Z
Introduction of Nutritional Substance into Epidural Space, Percutaneous Approach
→
3E0S37Z
Introduction of Electrolytic and Water Balance Substance into Epidural Space, Percutaneous Approach
→
3E0S3BZ
Introduction of Anesthetic Agent into Epidural Space, Percutaneous Approach
→
3E0S3GC
Introduction of Other Therapeutic Substance into Epidural Space, Percutaneous Approach
→
3E0S3HZ
Introduction of Radioactive Substance into Epidural Space, Percutaneous Approach
→
3E0S3KZ
Introduction of Other Diagnostic Substance into Epidural Space, Percutaneous Approach
→
3E0S3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Epidural Space, Percutaneous Approach
→
3E0S3SF
Introduction of Other Gas into Epidural Space, Percutaneous Approach
→
3E0S3TZ
Introduction of Destructive Agent into Epidural Space, Percutaneous Approach
→
3E0S7SF
Introduction of Other Gas into Epidural Space, Via Natural or Artificial Opening
→
3E0T33Z
Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach
→
3E0T3BZ
Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach
→
3E0T3GC
Introduction of Other Therapeutic Substance into Peripheral Nerves and Plexi, Percutaneous Approach
→
3E0T3TZ
Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach
→
3E0U028
Introduction of Oxazolidinones into Joints, Open Approach
→
3E0U029
Introduction of Other Anti-infective into Joints, Open Approach
→
3E0U0GB
Introduction of Recombinant Bone Morphogenetic Protein into Joints, Open Approach
→
3E0U0GC
Introduction of Other Therapeutic Substance into Joints, Open Approach
→
3E0U304
Introduction of Liquid Brachytherapy Radioisotope into Joints, Percutaneous Approach
→
3E0U305
Introduction of Other Antineoplastic into Joints, Percutaneous Approach
→
3E0U30M
Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach
→
3E0U328
Introduction of Oxazolidinones into Joints, Percutaneous Approach
→
3E0U329
Introduction of Other Anti-infective into Joints, Percutaneous Approach
→
3E0U33Z
Introduction of Anti-inflammatory into Joints, Percutaneous Approach
→
3E0U36Z
Introduction of Nutritional Substance into Joints, Percutaneous Approach
→
3E0U37Z
Introduction of Electrolytic and Water Balance Substance into Joints, Percutaneous Approach
→
3E0U3BZ
Introduction of Anesthetic Agent into Joints, Percutaneous Approach
→
3E0U3GB
Introduction of Recombinant Bone Morphogenetic Protein into Joints, Percutaneous Approach
→
3E0U3GC
Introduction of Other Therapeutic Substance into Joints, Percutaneous Approach
→
3E0U3HZ
Introduction of Radioactive Substance into Joints, Percutaneous Approach
→
3E0U3KZ
Introduction of Other Diagnostic Substance into Joints, Percutaneous Approach
→
3E0U3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Joints, Percutaneous Approach
→
3E0U3SF
Introduction of Other Gas into Joints, Percutaneous Approach
→
3E0U3TZ
Introduction of Destructive Agent into Joints, Percutaneous Approach
→
3E0U4GC
Introduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach
→
3E0V0GB
Introduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach
→
3E0V0GC
Introduction of Other Therapeutic Substance into Bones, Open Approach
→
3E0V305
Introduction of Other Antineoplastic into Bones, Percutaneous Approach
→
3E0V30M
Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach
→
3E0V328
Introduction of Oxazolidinones into Bones, Percutaneous Approach
→
3E0V329
Introduction of Other Anti-infective into Bones, Percutaneous Approach
→
3E0V33Z
Introduction of Anti-inflammatory into Bones, Percutaneous Approach
→
3E0V36Z
Introduction of Nutritional Substance into Bones, Percutaneous Approach
→
3E0V37Z
Introduction of Electrolytic and Water Balance Substance into Bones, Percutaneous Approach
→
3E0V3BZ
Introduction of Anesthetic Agent into Bones, Percutaneous Approach
→
3E0V3GB
Introduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach
→
3E0V3GC
Introduction of Other Therapeutic Substance into Bones, Percutaneous Approach
→
3E0V3HZ
Introduction of Radioactive Substance into Bones, Percutaneous Approach
→
3E0V3KZ
Introduction of Other Diagnostic Substance into Bones, Percutaneous Approach
→
3E0V3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Bones, Percutaneous Approach
→
3E0V3TZ
Introduction of Destructive Agent into Bones, Percutaneous Approach
→
3E0V4GC
Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach
→
3E0W305
Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach
→
3E0W30M
Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach
→
3E0W328
Introduction of Oxazolidinones into Lymphatics, Percutaneous Approach
→
3E0W329
Introduction of Other Anti-infective into Lymphatics, Percutaneous Approach
→
3E0W33Z
Introduction of Anti-inflammatory into Lymphatics, Percutaneous Approach
→
3E0W36Z
Introduction of Nutritional Substance into Lymphatics, Percutaneous Approach
→
3E0W37Z
Introduction of Electrolytic and Water Balance Substance into Lymphatics, Percutaneous Approach
→
3E0W3BZ
Introduction of Anesthetic Agent into Lymphatics, Percutaneous Approach
→
3E0W3GC
Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach
→
3E0W3HZ
Introduction of Radioactive Substance into Lymphatics, Percutaneous Approach
→
3E0W3KZ
Introduction of Other Diagnostic Substance into Lymphatics, Percutaneous Approach
→
3E0W3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Lymphatics, Percutaneous Approach
→
3E0W3TZ
Introduction of Destructive Agent into Lymphatics, Percutaneous Approach
→
3E0X33Z
Introduction of Anti-inflammatory into Cranial Nerves, Percutaneous Approach
→
3E0X3BZ
Introduction of Anesthetic Agent into Cranial Nerves, Percutaneous Approach
→
3E0X3GC
Introduction of Other Therapeutic Substance into Cranial Nerves, Percutaneous Approach
→
3E0X3TZ
Introduction of Destructive Agent into Cranial Nerves, Percutaneous Approach
→
3E0Y304
Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Percutaneous Approach
→
3E0Y305
Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach
→
3E0Y30M
Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
→
3E0Y328
Introduction of Oxazolidinones into Pericardial Cavity, Percutaneous Approach
→
3E0Y329
Introduction of Other Anti-infective into Pericardial Cavity, Percutaneous Approach
→
3E0Y33Z
Introduction of Anti-inflammatory into Pericardial Cavity, Percutaneous Approach
→
3E0Y36Z
Introduction of Nutritional Substance into Pericardial Cavity, Percutaneous Approach
→
3E0Y37Z
Introduction of Electrolytic and Water Balance Substance into Pericardial Cavity, Percutaneous Approach
→
3E0Y3BZ
Introduction of Anesthetic Agent into Pericardial Cavity, Percutaneous Approach
→
3E0Y3GC
Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Approach
→
3E0Y3HZ
Introduction of Radioactive Substance into Pericardial Cavity, Percutaneous Approach
→
3E0Y3KZ
Introduction of Other Diagnostic Substance into Pericardial Cavity, Percutaneous Approach
→
3E0Y3NZ
Introduction of Analgesics, Hypnotics, Sedatives into Pericardial Cavity, Percutaneous Approach
→
3E0Y3SF
Introduction of Other Gas into Pericardial Cavity, Percutaneous Approach
→
3E0Y3TZ
Introduction of Destructive Agent into Pericardial Cavity, Percutaneous Approach
→
3E0Y4GC
Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Endoscopic Approach
→
3E0Y704
Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Via Natural or Artificial Opening
→
3E0Y705
Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening
→
3E0Y70M
Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening
→
3E0Y7SF
Introduction of Other Gas into Pericardial Cavity, Via Natural or Artificial Opening
→